Teva Pharmaceutical Industries Ltd (NYSE:TEVA)‘s stock had its “buy” rating reaffirmed by analysts at Mizuho in a note issued to investors on Monday. They currently have a $64.00 price target on the stock. Mizuho’s target price points to a potential upside of 29.37% from the company’s previous close.
TEVA has been the topic of a number of other research reports. Oppenheimer Holdings Inc. set a $66.00 price objective on Teva Pharmaceutical Industries and gave the company a “buy” rating in a report on Monday, September 12th. Credit Suisse Group AG reissued a “neutral” rating and set a $51.63 price target (down previously from $59.00) on shares of Teva Pharmaceutical Industries in a research note on Thursday, August 25th. Leerink Swann set a $61.00 price target on Teva Pharmaceutical Industries and gave the stock an “outperform” rating in a research note on Wednesday, August 31st. Vetr raised Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating and set a $60.02 price target on the stock in a research note on Monday, August 1st. Finally, Jefferies Group decreased their price target on Teva Pharmaceutical Industries from $72.00 to $69.00 and set a “buy” rating on the stock in a research note on Thursday, July 14th. Seven analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $67.54.
Shares of Teva Pharmaceutical Industries (NYSE:TEVA) opened at 49.47 on Monday. The firm’s 50-day moving average price is $51.78 and its 200 day moving average price is $53.03. Teva Pharmaceutical Industries has a 1-year low of $48.01 and a 1-year high of $66.55. The firm has a market cap of $45.22 billion, a PE ratio of 33.05 and a beta of 0.82.
Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.20 by $0.05. The business earned $5 billion during the quarter, compared to analysts’ expectations of $4.86 billion. During the same period in the prior year, the firm posted $1.43 EPS. Teva Pharmaceutical Industries’s revenue for the quarter was up 1.4% compared to the same quarter last year. On average, equities research analysts forecast that Teva Pharmaceutical Industries will post $5.26 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 8th. Stockholders of record on Monday, August 22nd were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, August 18th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 2.75%.
Several hedge funds have recently added to or reduced their stakes in the company. Sharkey Howes & Javer increased its stake in Teva Pharmaceutical Industries by 21.7% in the second quarter. Sharkey Howes & Javer now owns 2,008 shares of the company’s stock worth $101,000 after buying an additional 358 shares during the last quarter. Hudock Capital Group LLC boosted its stake in shares of Teva Pharmaceutical Industries by 37.6% in the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company’s stock worth $103,000 after buying an additional 564 shares during the period. WFG Advisors LP boosted its stake in shares of Teva Pharmaceutical Industries by 14.0% in the second quarter. WFG Advisors LP now owns 2,080 shares of the company’s stock worth $104,000 after buying an additional 256 shares during the period. Flow Traders U.S. LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $105,000. Finally, Kistler Tiffany Companies LLC boosted its stake in shares of Teva Pharmaceutical Industries by 3.1% in the second quarter. Kistler Tiffany Companies LLC now owns 2,135 shares of the company’s stock worth $107,000 after buying an additional 64 shares during the period.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.
Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.